Oct 17, 2023 8:00 am EDT Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Oct 11, 2023 8:00 am EDT Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
Sep 14, 2023 4:05 pm EDT Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Jun 27, 2023 4:05 pm EDT Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
May 11, 2023 4:05 pm EDT Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
Mar 23, 2023 4:50 pm EDT Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Mar 8, 2023 7:00 am EST Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Feb 10, 2023 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Dec 15, 2022 7:00 am EST Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
